Over the past few years, the world has undergone considerable changes in the area of pricing and reimbursement (P&R). Escalating healthcare expenditure has led payer organisations to focus increasingly on cost containment. Although the reality today is that every new drug trying to gain market access has to prove its clinical, economic and even social value, too few companies involved in in-licensing activities for new products include a P&R assessment in their deal making process. A new PharmaVentures' report, lt;igt;Deal Making in the New Healthcare Landscape: Leveraging your Deal through Pricing and Reimbursement Considerationslt;/igt;, will teach you how to use this new P&R reality to gain a competitive advantage when licensing a product, and will explain how each factor has an impact on the value of a deal. This article highlights parts of three of the seven chapters of the report.